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To detect replicating viruses, dendritic cells (DCs) utilize cytoplasmic retinoic acid
inducible gene-(RIG) I-like receptors (RLRs), which play an essential role in the
subsequent activation of antiviral immune responses. In this study, we aimed to explore
the role of the mammalian target of rapamycin (mTOR) in the regulation of RLR-triggered
effector functions of human monocyte-derived DCs (moDCs) and plasmacytoid DCs
(pDCs). Our results show that RLR stimulation increased the phosphorylation of the
mTOR complex (mTORC) 1 and mTORC2 downstream targets p70S6 kinase and Akt,
respectively, and this process was prevented by the mTORC1 inhibitor rapamycin as well
as the dual mTORC1/C2 kinase inhibitor AZD8055 in both DC subtypes. Furthermore,
inhibition of mTOR in moDCs impaired the RLR stimulation-triggered glycolytic switch,
which was reflected by the inhibition of lactate production and downregulation of key
glycolytic genes. Blockade of mTOR diminished the ability of RLR-stimulated moDCs
and pDCs to secret type I interferons (IFNs) and pro-inflammatory cytokines, while it did
not affect the phenotype of DCs. We also found that mTOR blockade decreased the
phosphorylation of Tank-binding kinase 1 (TBK1), which mediates RLR-driven cytokine
production. In addition, rapamycin abrogated the ability of both DC subtypes to promote
the proliferation and differentiation of IFN-y and Granzyme B producing CD8 + T cells.
Interestingly, AZD8055 was much weaker in its ability to decrease the T cell proliferation
capacity of DCs and was unable to inhibit the DC-triggered production of IFN-y and
Granyzme B by CD8 + T cells. Here we demonstrated for the first time that mTOR
positively regulates the RLR-mediated antiviral activity of human DCs. Further, we
show that only selective inhibition of mTORC1 but not dual mTORC1/C2 blockade
suppresses effectively the T cell stimulatory capacity of DCs that should be considered
in the development of new generation mTOR inhibitors and in the improvement of
DC-based vaccines.
Keywords: dendritic cell, mTOR, RLR signaling, antiviral response, T cell stimulation
Abbreviations: BM-DC, bone marrow-derived DC; cDC, conventional DC; DC, dendritic cell; HIF1A, hypoxia-inducible
factor 1-alpha; HK2, hexokinase 2; IFN, interferon; LDHA, lactate dehydrogenase A; MAPK, mitogen activated protein
kinase; MDA5, melanoma differentiation-associated protein 5; moDC, monocyte-derived DC; mTOR(C), mammalian target
of rapamycin (complex); p70S6k, p70S6 kinase; pDC, plasmacytoid DC; polyI:C, polyinosinic:polycytidylic acid; PRR, pattern
recognition receptor; RIG-I, retinoic-acid inducible gene I; RLR, RIG-I-like receptors; TBK1, tank-binding kinase 1; TLR,
toll-like receptors; VSV, vesicular stomatitis virus.
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INTRODUCTION
Dendritic cells (DCs) play an essential role in the initiation
of efficient immune responses against viral infections. As
sentinels of the immune system DCs express a diverse set
of pattern recognition receptors (PRRs) including Toll-like
receptors (TLRs) and retinoic acid inducible gene-(RIG) I-like
receptors (RLRs), which makes them able to recognize and bind
to a wide range of viral nucleic acids and other conserved
molecular signatures (1, 2). Upon recognition of viral infection,
DCs undergo profound phenotypic and functional changes,
which endows them with the ability to successfully mount
an antiviral state and the capability to migrate to secondary
lymphoid tissues, where they prime adaptive immune response
as well (3). The PRR-triggered responses of DCs are tightly
controlled by a number of regulatory mechanisms, among them
the mammalian target of rapamycin (mTOR) signaling pathway
has received great attention lately.
Numerous studies have demonstrated that the mTOR
pathway plays a central role in coordinating the development,
differentiation and function of various immune cells including
DCs (4). Besides, the mTOR pathway was found to be
involved in the replication of a number of RNA and DNA
viruses, which utilize host signaling pathways to enhance viral
mRNA translation (5). mTOR is an evolutionarily conserved
serine/threonine kinase that in response to environmental cues
and intracellular signals controls cell growth, proliferation,
metabolism and immune cell function. The mTOR protein
is known to function as a component of two distinct
multiprotein complexes: the rapamycin-sensitive mTOR complex
1 (mTORC1) and rapamycin-resistant mTORC2. Activation of
mTORC1 leads to the phosphorylation of p70S6 kinase (p70S6K)
and eukaryotic translation initiation factor 4E-binding protein 1
(4E-BP1), which promotes ribosome assembly and translation.
Active mTORC2 phosphorylates multiple proteins including Akt,
which couples extracellular signals to mTORC1 activation and
other pathways controlling cell proliferation and survival (6).
The role of mTOR in DC biology has been broadly
studied at both cellular and organism level using mTOR
specific inhibitors (7). The immunosuppressive drug rapamycin
is a potent allosteric mTOR inhibitor, which upon forming
a complex with the intracellular FK506-binding protein 12
(FKBP12) inhibits mTORC1 downstream signaling while not
affecting mTORC2 activity (8). It has been demonstrated first
in plasmacytoid DCs (pDCs), which are the major cells in
antiviral defense, that rapamycin pre-conditioning suppressed
TLR9-induced type I interferon (IFN) production by both
mouse and human pDCs (9). Rapamycin was also shown to
inhibit the TLR9-induced release of type I IFNs from mouse
myeloid DCs and Fms-like tyrosine kinase 3 ligand-dependent
DCs as well (10). Interestingly, mTOR inhibition by rapamycin
has been found to differentially regulate the cell surface
TLR- and CD40 ligand-stimulated production of inflammatory
cytokines and allogeneic T cell stimulatory capacity of human
monocyte-derived DCs (moDCs) and CD1c + conventional
DCs (cDCs) (11). Furthermore, inhibition of mTOR decreased
the survival and increased the apoptosis of differentiating
moDCs, while did not interfere with the differentiation of
CD1c + cDCs. The second generation mTOR inhibitors such
as AZD8055 and AZD2014, target the ATP binding site in the
mTOR kinase domain, thus are able to inhibit the activity of
both mTOR complexes. Rapamycin and the dual mTORC1/2
mTOR kinase inhibitor AZD2014 have been shown to reduce
the generation of murine DCs from bone-marrow (BM-DC)
(12). AZD8055 was demonstrated to induce a tolerogenic
phenotype in BM-DC, that was indicated by the suppressed
expression of major histocompatibility complex II (MHC II)
and costimulatory molecules as well as by the decreased
capacity to induce CD4 + T cell proliferation upon TLR4
stimulation (13). Previously we have reported that mTOR is
also essential to the endosomal TLR3-mediated secretion of
type I and III IFNs of human moDCs and blood circulating
CD1c + cDCs (14). Thus, as outlined above, a growing
body of evidence indicates that mTOR signaling shapes TLR-
mediated DC responses, however its ability to modulate RLR-
mediated activation and effector function of human DCs has not
been explored yet.
RLRs are cytosolic viral sensors, which upon recognition of
viral replication intermediates trigger signaling cascades leading
to the production of type I IFNs and inflammatory cytokines
(15). RIG-I and melanoma differentiation-associated protein
5 (MDA5), two major members of RLRs were reported to
have distinct ligand preferences: RIG-I primarily recognizes
short RNA sequences with 5’ triphosphate groups, while MDA5
predominantly recognizes long dsRNAs (16). We have previously
published that similarly to blood circulating cDCs, moDCs
constitutively express RLRs to sense foreign nucleic acids (17,
18). On the contrary, RIG-I and MDA5 levels are very low in
resting pDCs, but can be greatly upregulated upon endosomal
TLR stimulation. These observations indicate that, although,
RLRs are absent from resting pDCs, they are inducible upon
viral infections, thus contribute to the late phase of type I IFN
responses of pDCs (18).
Many molecules have been previously identified as a regulator
of RLR-mediated antiviral and inflammatory responses such as
LGP2 (19), NOD2 (20), NLRX1 (17) or TRIM29 (21); however,
to the best of our knowledge, the involvement of mTOR in RLR
signaling of human DCs has not been investigated yet. Therefore,
the goal of the present study was to reveal whether mTOR
signaling contributes to the RLR-induced cytokine responses and
T cell stimulatory potential of human moDCs and pDCs.
MATERIALS AND METHODS
Isolation and Culturing of Primary
Human Cells
The collection of human heparinized leukocyte-enriched buffy
coat samples complied with the guidelines of the Helsinki
Declaration and was approved by National Blood Transfusion
Service and the Regional and Institutional Ethics Committee of
the University of Debrecen, Faculty of Medicine (OVSzK 3572-
2/2015/5200, Hungary). Buffy coat were obtained from healthy
blood donors and peripheral blood mononuclear cells (PBMC)
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were separated by Ficoll-Paque Plus (Amersham Biosciences,
Uppsala, Sweden) gradient centrifugation.
Monocytes were purified from PBMCs by positive selection
using magnetic cell separation with anti-CD14-conjugated
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
Freshly isolated cells were seeded in 24-well cell culture plates
at a density of 1 × 106 cells/ml in RPMI 1640 medium (Sigma-
Aldrich, St. Louis, MO, United States) supplemented with 10%
heat-inactivated FBS (Life Technologies Corporation, Carlsbad,
CA, United States), 2 mM L-glutamine, 100 U/ml penicillin,
100 µg/ml streptomycin (all from Sigma-Aldrich), 80 ng/ml GM-
CSF (Gentaur Molecular Products, London, United Kingdom)
and 50 ng/ml IL-4 (PeproTech, Brussels, Belgium) for 5 days.
Human pDCs were isolated from PBMCs by positive selection
using the human CD304 (BDCA-4/Neuropilin-1) MicroBead Kit
(Miltenyi Biotec) then cultured in 96-well cell culture plates
at a density of 1 × 105 cells/200 µl in RPMI 1640 medium
(Sigma-Aldrich) supplemented with 10% heat-inactivated FBS
(Life Technologies Corporation), 2 mM L-glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin (all from Sigma-Aldrich), and
50 ng/ml recombinant human IL-3 (PeproTech).
Allogenic, naive CD8 + T cells were isolated from PBMC
using the human naïve CD8 + T cell isolation kit (Miltenyi
Biotec), and were used for DC-T cell co-culture experiments as
described below.
All cells were incubated at 37◦C in 5% CO2 humidified
atmosphere.
GEN2.2 Cell Line
The human pDC cell line (GEN2.2) (22) used in our experiments
was provided by Dr. Joel Plumas and Dr. Laurence Chaperot
(Research and Development Laboratory, French Blood Bank
Rhône-Alpes, Grenoble, France) and was deposited with the
CNCM (French National Collection of Microorganism Cultures)
under the number CNCMI-2938. GEN2.2 cells were grown on
a layer of mitomycin C (Sigma-Aldrich)-treated murine MS5
feeder cells (Cat. No. ACC 441, Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures, Braunschweig,
Germany) in RPMI 1640 medium (Sigma-Aldrich) supplemented
with 10% heat-inactivated FBS (Life Technologies Corporation),
2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin
(all from Sigma-Aldrich) and 5% non-essential amino acids (Life
Technologies Corporation). For experiments, the GEN2.2 cells
were removed from the feeder layer and seeded on 24-well plates
at a concentration of 5× 105 cells/500 µl in complete RPMI 1640
medium (Sigma-Aldrich). Cell lines were grown and incubated at
37◦C in 5% CO2 humidified atmosphere.
Cell Stimulation
Before stimulation of moDCs half of the medium was
removed and replaced by fresh complete medium supplemented
with rapamycin (Merck Millipore, Darmstadt, Germany) or
AZD8055 (Selleckchem, Houston, TX, United States) at a final
concentration of 100 nM. Medium containing DMSO (final
concentration 0.001%) was used as control treatment. After a
2 h incubation cells were stimulated with 3p-hpRNA (InvivoGen,
San Diego, CA, United States), a specific agonist of RIG-I or high
molecular weight polyinosinic:polycytidylic acid (polyI:C-HMW;
InvivoGen) complexed with the transfection reagent LyoVecTM
(InvivoGen), at a final concentration of 0.5 µg/ml and 1 µg/ml,
respectively, for the indicated time periods.
To induce RIG-I/MDA5 expression in GEN2.2 cells and
primary pDCs, cells were pre-treated with the TLR9 agonist
CpG-A (Hycult Biotech, Uden, The Netherlands) for 16 h
as described previously (17, 23). Thereafter, the cells were
washed, re-seeded in fresh, complete RPMI 1640 medium
supplemented with mTOR inhibitors then stimulated with 3p-
hpRNA/LyoVecTM or polyI:C-HMW/LyoVecTM complexes as
described above for moDCs.
For live virus infection moDCs and CpG-A pre-treated pDCs
were infected with vesicular stomatitis virus (VSV) Indiana
serotype (VR-1238, ATCC, Manassas, VA, United States) at a
MOI of 1 for 18 h.
DC- T Cell Co-culture
Following activation, moDCs and primary pDCs were washed
twice with cell culture medium and then co-cultured with freshly
isolated, allogeneic naïve CD8 + T cells in RPMI 1640 medium
(Sigma-Aldrich) supplemented with 10% heat-inactivated FBS
(Life Technologies Corporation), 2 mM L-glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin (all from Sigma-Aldrich) in
the presence of 1 µg/ml anti-human CD3 mAb (BD Biosciences,
Franklin, Lakes, NJ, United States). For proliferation assays, T
cells were previously labeled with 0.5 µM carboxyfluorescein
succinimidyl ester (CFSE, Invitrogen) and seeded on 96-well
round bottom plates at a ratio of 2 × 104 DC: 2 × 105 T cell
in 200 µl complete RPMI 1640 medium. After 5 days of co-
cultivation, CFSE fluorescence intensities of T cells were detected
in the FL1 (530 ± 15 nm) channel on a BD FACSCalibur
flow cytometer (BD Biosciences). For intracellular cytokine
staining naïve CD8 + T cells were seeded on 48-well cell culture
plates at a ratio of 1:10 (1 × 105 DCs; 1 × 106 T cells) in
500 µl complete RPMI 1640 medium and after 6 days of co-
cultivation were restimulated with 0.1 µg/ml phorbol myristate
acetate and 1 µg/ml ionomycin (both from Sigma-Aldrich) in
the presence of the protein transport inhibitor monensin (BD
Biosciences) for 5 h. Thereafter, the cells were stained with anti-
CD8-FITC (clone SK1) and isotype matched control antibody
(both from BioLegend, San Diego, CA, United States), fixed
and permeabilized by the BD Cytofix/Cytoperm solution (BD
Biosciences). Cells were then labeled with APC-conjugated anti-
IFN-y (clone 4S.B3) and anti-Granzyme B (clone QA18A28)
antibodies and their isotype matched control antibodies (all
from BioLegend). Fluorescence intensities were measured
with FACSCalibur flow cytometer (BD Biosciences) and data
were analyzed with FlowJo software (TreeStar, Ashland, OR,
United States).
Flow Cytometric Analysis of DCs
Phenotypical analysis of moDCs and GEN2.2 cells was performed
by multicolor flow cytometry using anti-CD40-FITC (clone
M5E2), anti-CD80-FITC (clone 2D10), anti-HLA-ABC-FITC
(clone W6/32), anti-CD86-PE (clone IT2.2), anti-HLDA-DQ-
PE (clone HLADQ1), anti-CD83-PeCy5 (HB15e), and isotype-
matched control antibodies (all from BioLegend). Cell viability
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was assessed by 7-aminoactinomycin D (7-AAD; Sigma–Aldrich)
staining for 15 min immediately before flow cytometric analysis.
Fluorescence intensities were measured with FACSCalibur flow
cytometer (BD Biosciences) and data were analyzed with FlowJo
software (TreeStar).
Western Blotting
For western blotting 5 × 105 cells were lysed in Laemmli buffer,
heated at 100◦C for 10 min, separated on 7.5 or 10% SDS-PAGE
then electro-transferred to nitrocellulose membranes (Bio-Rad
Laboratories GmbH, Munich, Germany). Non-specific binding
sites were blocked with 5% non-fat dry milk diluted in TBS
Tween buffer (50 mM Tris, 0.5 M NaCl, 0.05% Tween-20,
pH 7.4). Membranes were probed with the anti-RIG-I (clone
D14G6), anti-MDA5 (clone D74E4), anti-phospho-Akt (Ser473;
clone D9E), anti-Akt (clone 11E7), anti-phospho-p70S6 kinase
(Thr389; clone D5U10) and anti-p70S6 kinase (clone 49D7),
anti-phospho-Tank-binding kinase 1 (TBK1; clone D1B4), anti-
TBK1 (clone D52C2), anti-phospho-p38 (clone 28B10) and
anti-p38 antibodies (catalog number 9212) (all from Cell
Signaling, Danvers, MA, United States). Beta-actin was used as
a loading control (clone C4; Santa Cruz Biotechnology). The
bound primary antibodies were conjugated with anti-mouse
or anti-rabbit horseradish peroxidase-conjugated secondary
antibodies (GE Healthcare, Little Chalfont, Buckinghamshire,
United Kingdom) at a dilution of 1:5000 and 1:10000 respectively
and were visualized by the ECL system using SuperSignal
West Pico or Femto chemiluminescent substrate (Thermo
Fisher Scientific, Rockford, IL, United States) and X-ray film
exposure. Densitometric analysis of immunoreactive bands was
performed using Image Studio Lite Software version 5.2 (LI-COR
Biosciences, Lincoln, NE, United States).
Quantitative Real Time PCR
Total RNA was isolated from 5 × 105 cells using Tri Reagent
(Molecular Research Center, Inc., Cincinnati, OH, United States).
1 µg of total RNA was treated with DNase I (Thermo Fisher
Scientific, Waltham, MA, United States) to exclude amplification
of genomic DNA then reverse transcribed into cDNA using
the High Capacity cDNA RT Kit of Applied Biosystems (Foster
City, CA, United States). Gene expression assays were purchased
from Thermo Fisher Scientific for IL-6, TNF, hexokinase 2
(HK2), lactate dehydrogenase A (LDHA), hypoxia-inducible
factor 1-alpha (HIF1A), and from Integrated DNA Technologies
(Coralville, IA, United States) for PPIA (cyclophilin A) and
IFNA1. Quantitative PCR was performed using the ABI StepOne
Real-Time PCR System (Applied Biosystems) and cycle threshold
values were determined using the StepOne v2.1 Software
(Applied Biosystems). The relative amount of mRNA was
obtained by normalizing to the PPIA housekeeping gene in
each experiment.
Assessment of Cytokines and Lactic
Acid in Cell Supernatants
Cell culture supernatants were collected at the indicated time
points. IFN-α levels were measured by the VeriKineTM Human
Interferon Alpha ELISA kit (PBL Interferon Sources, Piscataway,
NJ, United States), whereas TNF and IL-6 levels were determined
by the BD OptEIA human ELISA kits (BD Biosciences) according
to the manufacturer’s instructions. Lactate production of the cells
was detected using the Glycolysis Cell-Based Assay Kit (Cayman
Chemical, Ann Arbor, Michigan, United States) according to the
manufacturer’s protocol. Absorbance measurements were carried
out by a Synergy HT microplate reader (Bio-Tek Instruments,
Winooski, VT, United States) at 450 nm for cytokine detection
and at 490 nm for lactate assay.
Statistical Analysis
Statistical analysis was performed using ANOVA, followed by
Bonferroni post hoc test by GraphPad Prism v.6. software
(GraphPad Software Inc., La Jolla, CA, United States). Differences
were considered to be statistically significant at p< 0.05.
RESULTS
The mTOR Pathway Is Activated by
RLR-Mediated Stimuli in moDCs
It is well known that TLR ligands activate mTORC1 and
mTORC2 in innate immune cells (10, 11); however, whether
mTOR signaling is integrated in the RLR signaling pathway of
human DCs has not been investigated yet. To our studies, we
used moDCs, which are closely related to inflammatory DCs
and represent the best-studied model for human DC biology
and for immunotherapy using DC vaccines against infectious
diseases or cancer (24, 25). In order to analyze the role of
mTOR, moDCs were pre-treated with rapamycin, an mTORC1-
specific inhibitor, or AZD8055, which inhibits the activity of
both mTORC1 and mTORC2, at clinically relevant doses prior
to any other stimulation. Based on our previous publication the
100 nM concentration of rapamycin effectively inhibits mTOR
signaling in moDCs while not affecting cell viability (14). After
confirming that exposure to the same dose of AZD8055 did not
alter cell viability (Supplementary Figures 1A,B, 2A,B), we have
challenged the cells with 100 nM of both of the mTOR inhibitors
for 2 h prior to RLR stimulation.
As a first step we tested whether mTOR inhibition affects the
expression of the RLR receptors. Our results show that a 2 h
treatment with rapamycin or AZD8055 does not alter the protein
levels of RIG-I and MDA5 as compared to the solvent/vehicle
control treated cells (Supplementary Figures 3A,B).
To investigate whether RLR signaling drives mTOR activation
in moDCs, we have analyzed the phosphorylation of p70S6K
(Thr389), a major substrate of mTORC1 and Akt (Ser 473),
the downstream target of mTORC2. Thus, 5-day moDCs
were pre-treated with the mTOR inhibitors for 2 h and then
stimulated with the RIG-I agonist 3p-hpRNA for different
time periods (Figures 1A,B). Our results show that RIG-
I stimulation significantly increased the phosphorylation of
p70S6K showing a peak at 1 h of activation. Phosphorylation
of p70S6K was markedly inhibited in the cells pre-treated with
rapamycin or AZD8055. The phosphorylation of Akt at Ser473
was slightly but significantly increased upon RIG-I activation
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FIGURE 1 | RLR stimulation increases mTORC1 and mTORC2 activity in moDCs that is effectively inhibited by rapamycin and AZD8055 pre-treatment. Immature
moDCs were pre-treated with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h then stimulated with 3p-hpRNA (0.5 µg/ml) (A,B) or
polyI:C (1 µg/ml) (C,D) for different time periods. Kinetics of p70S6K and Akt phosphorylation were determined by western blotting. (A,C) Representative blots are
shown. (B,D) Bar graphs represent the mean ± SD of at least 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.01 vs. control; #p < 0.05, ###p < 0.001,
####p < 0.0001. ND, not determined.
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(Figures 1A,B) that was effectively inhibited by AZD8055.
In parallel experiments, moDCs were stimulated with polyI:C
(Figures 1C,D), which in complex with the transfection reagent
LyoVec is a ligand for both cytoplasmic RIG-I and MDA5.
Nevertheless, studies reported that the polyI:C/LyoVec complex
is preferentially recognized by MDA5 (26). Following stimulation
with polyI:C the phosphorylation of both p70S6K and Akt was
significantly increased. Rapamycin inhibited the phosphorylation
of only p70S6K, whereas AZD8055 efficiently abrogated the
phosphorylation of p70S6K and Akt both in resting and activated
cells. Thus, our results demonstrate that RLR stimuli increase the
activity of mTOR signaling, which can be effectively repressed
by the mTORC1 specific inhibitor rapamycin and the dual
mTORC1/2 inhibitor AZD8055 (Figures 1C,D).
mTOR Controls the RLR-Mediated
Activation of moDCs
Previously we have described that activation of moDCs by RIG-I
results in a metabolic switch from oxidative phosphorylation to
glycolysis, which promotes their type I IFN production and T cell
priming ability (23). In contrast, we found that RIG-I-mediated
antiviral responses of pDCs do not require glycolysis, implying
that moDCs and pDCs have distinct metabolic profile upon
RIG-I stimulation (23). Since it has been recognized that mTOR
signaling supports the shift toward glycolysis upon TLR-mediated
DC activation (27), we sought to reveal the role of mTOR
in the glycolytic reprogramming of RLR-stimulated moDCs as
well. Therefore, we examined the expression of glycolysis-related
genes and levels of lactate in RLR-stimulated moDCs upon
mTOR blockade. We found that both inhibitors abrogated the
upregulation of LDHA, HK2 and HIF1A (Figures 2A,B) and
reduced the production of lactate (Figures 2C,D) in 3p-hpRNA-
and polyI:C-stimulated cells. These results indicate that mTOR is
essential to the RLR-mediated glycolytic changes of moDCs.
Knowing that the shift to glycolysis, which provides energy for
activation and cytokine production of cells, is mediated through
mTOR, in the next step we investigated its involvement in the
phenotypic and functional changes of RLR-stimulated moDCs.
Following pre-treatment with rapamycin or AZD8055 cells were
stimulated with 3p-hpRNA and polyI:C for 24 h then the
expression of various membrane-bound molecules including the
activation marker CD83, co-stimulatory molecules (CD80, CD86
and CD40) and MHC molecules (HLA-DQ and HLA-ABC) was
measured by flow cytometry (Supplementary Figures 4A,B).
Neither rapamycin nor AZD8055 altered the baseline and RLR-
induced expression of the tested cell surface molecules. Next
we analyzed the expression of type I IFNs, which are the major
antiviral mediators as well as the induction of IL-6 and TNF pro-
inflammatory cytokines both at the protein and mRNA levels. We
found that resting moDCs do not secrete type I IFNs and only
weekly produce inflammatory cytokines that is not affected by
mTOR blockade. The RLR-triggered production of IFN-α, one
of the major type I IFNs produced by moDCs and the secretion
of IL-6 and TNF pro-inflammatory cytokines was significantly
abrogated upon mTOR inhibition (Figures 3A,B). In line with
that, we found that blocking of mTOR activity was able to
decrease the RLR-driven upregulation of IFNA1, IL-6 and TNF
mRNA levels (Supplementary Figures 5A–D). To strengthen
our observations, we also performed experiments with live virus.
Following pre-treatment with rapamycin and AZD8055 moDCs
were stimulated with VSV at a MOI of 1 for 18 h. As with the
synthetic ligands, we found that mTOR blockade significantly
reduced the VSV infection-induced production of IFN-α, IL-6
and TNF (Figure 3C).
Since RLR signaling culminates in the activation of the
serine/threonine-protein kinase TBK1, which is involved in the
production of both pro-inflammatory and antiviral cytokines (28,
29), we analyzed TBK1 activity by detecting its phosphorylation
at serine 172 (Figures 4A–D). Our results indicate that
RLR stimulation increases the level of TBK1 phosphorylation,
which can be significantly decreased upon mTOR inhibition.
The mitogen activated protein kinase (MAPK) p38 was also
reported to be essential to the RIG-I-mediated interferon
production and activation of DCs (30). However, measuring
the phosphorylation levels of p38 (Thr180/Tyr182), we did
not observed any differences upon RLR stimulation or mTOR
blockade (Supplementary Figures 6A–D).
All these data demonstrate that inhibition of mTORC1 as well
as mTORC1/C2 did not restrained the phenotypic maturation
of RLR-stimulated moDCs, while significantly reduced their
cytokine responses probably through decreasing TBK1 activity.
RLR Stimulation Enhances mTOR
Activity in pDCs
To determine the importance of mTOR in RLR-mediated
antiviral responses of other DC subsets next we focused our
interest on pDCs, which are best known for their ability
to produce large amounts of type IFNs as well as various
pro-inflammatory cytokines in response to a viral infection
(31). Due to the limiting number of circulating pDCs in
the peripheral blood we performed some of our experiments
with the human GEN2.2 pDC cell line, which shows similar
phenotypic and functional properties to primary human pDCs
(32, 33). Nevertheless, the cytokine profile and T cell stimulatory
potential of pDCs were confirmed with primary human pDCs
isolated from peripheral blood. Based on our previous findings
moDCs express baseline levels of RLRs, while pDCs require
a pre-treatment with the TLR9 agonist CpG-A to induce
the expression of RIG-I and MDA5 (18). Therefore, GEN2.2
cells or primary pDCs were pre-treated with a low dose of
CpG-A for 16 h then washed thoroughly prior to any other
treatments. First, to investigate the role of mTOR in RLR-
dependent signaling we examined whether mTOR blockade
modifies the expression of RLR receptors in pDCs. As with
moDCs, a 2 h treatment with rapamycin and AZD8055 did not
induce any changes in the protein levels of RIG-I and MDA5
(Supplementary Figures 3C,D).
Next, we determined whether mTOR signaling affects the
activation of RLRs in pDCs similarly to moDCs, therefore we
analyzed the phosphorylation rate of p70S6K (Thr389) and Akt
(Ser473), the downstream targets of mTORC1 and mTORC2,
respectively. GEN2.2 cells were pre-conditioned with 100 nM
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FIGURE 2 | The RLR-mediated shift to glycolysis is impaired upon mTOR inhibition in moDCs. Immature moDCs were pre-treated with vehicle control, 100 nM
rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h and then stimulated with 3p-hpRNA (0.5 µg/ml) (A,C) or polyI:C (1 µg/ml) (B,D) for 12 h. (A,B) The expression
of LDHA, HK2 and HIF1A was assessed at the mRNA level by real-time PCR. Bar graphs represent the mean ± SD of 4 independent experiments. (C,D) Lactate
concentrations were measured from cell culture supernatants. Bar graphs represent the mean ± SD of 6 independent experiments. *p < 0.05, **p < 0.01,
***p < 0.01, ****p < 0.0001 vs. control; ##p < 0.01, ###p < 0.001, ####p < 0.0001.
rapamycin or AZD8055 for 2 h then stimulated with RLR
agonist and the kinetics of Akt and p70S6K phosphorylation was
determined by western blotting. The time-dependent analysis
shows that similar to moDCs, stimulation of pDCs with 3p-
hpRNA (Figures 5A,B) and polyI:C (Figures 5C,D) significantly
increased the phosphorylation of p70S6K and Akt showing a
peak at 1 h after challenge. Our results further demonstrate
that pre-treatment with rapamycin successfully abrogated the
phosphorylation of only p70S6K both in resting and activated
cells, whereas the dual mTORC1/2 inhibitor, AZD8055 blocked
the phosphorylation of both mTOR targets. We also found that
pre-conditioning by rapamycin alone leads to an increase in Akt
phosphorylation that can be explained by the loss of negative
feedback loop from mTORC1 and p70S6K (34). These results
are in line with data obtained in moDCs showing that mTOR
activity is increased by RLR stimuli suggesting its involvement in
RLR-mediated innate immune responses of human pDCs as well.
mTOR Modulates the RLR-Triggered
Maturation of pDCs
Because RLR engagement was found to activate mTOR signaling
in pDCs, we were also curious how mTOR inhibition could
impact the RLR-induced phenotypic and functional changes of
pDCs. Pre-treatment with rapamycin or AZD8055 was followed
by stimulation with 3p-hpRNA and polyI:C for 24 h and then
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FIGURE 3 | The RLR-mediated production of IFN-α and pro-inflammatory cytokines is decreased upon mTOR blockade in moDCs. Immature moDCs were
pre-treated with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h and then stimulated with 3p-hpRNA (0.5 µg/ml) (A), polyI:C (1 µg/ml)
(B) or VSV (MOI 1) (C). (A–C) IFN-α, IL-6 and TNF protein levels were measured by ELISA 24 h after 3p-hpRNA and polyI:C activation as well as 18 h after VSV
stimulation. Data are shown as mean ± SD from 5 to 8 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.01, ****p < 0.0001 vs. control; ###p < 0.001,
####p < 0.0001. ND, not determined.
the expression of the same panel of membrane-bound molecules
as for moDCs was analyzed by flow cytometry (Supplementary
Figures 7A,B). Similar to moDCs, mTOR blockade did not affect
the baseline level or RLR-triggered expression of the investigated
cell surface molecules. Interestingly, RLR stimulation increased
significantly the expression of the CD83 activation marker, which
was further enhanced by AZD8055 pre-treatment.
Next, to identify the impact of mTOR activity on the
effector functions of pDCs, the secretion of IFN-α and pro-
inflammatory cytokines was analyzed in RLR-activated cells
upon pre-incubation with mTOR inhibitors. In GEN2.2 cells,
inhibition of mTORC1 with rapamycin or mTORC1/2 with
AZD8055 alone neither induced IFN-α production nor altered
the secretion of IL-6 and TNF. Consistent with the data
obtained with moDCs, 3p-hpRNA (Figure 6A) and polyI:C
(Figure 6B) significantly increased the production of IFN-
α, IL-6 and TNF cytokines, which was prevented upon pre-
treatment with rapamycin or AZD8055. To further confirm our
results, we also tested the cytokine production of live virus
infected cells and found that inhibition of mTOR impaired
profoundly the VSV-induced release of IFN-α, IL-6 and TNF as
well (Figure 6C).
Similar to moDCs, we also analyzed the phosphorylation levels
of TBK1 (Figures 7A–D) and p38 (Supplementary Figures 8A–
D) to reveal the mechanism underlying the effects of mTOR
inhibitors on RLR-mediated cytokine production of pDCs. In line
with our observation on moDCs, we found that RLR-mediated
activation of TBK1 was significantly inhibited in the presence
of rapamycin or AZD8055 in GEN2.2 cells as well, whereas the
phosphorylation of p38 was not affected.
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FIGURE 4 | RLR stimulation enhances TBK1 activity in moDCs that is decreased by rapamycin and AZD8055 pre-treatment. Immature moDCs were pre-treated
with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h then stimulated with 3p-hpRNA (0.5 µg/ml) (A,C) or polyI:C (1 µg/ml) (B,D) for
different time periods. Kinetics of TBK1 phosphorylation were determined by western blotting. (A,B) Representative blots are shown. (C,D) Bar graphs represent the
mean ± SD of at least 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.01, ****p < 0.0001 vs. control; ##p < 0.01, ####p < 0.0001.
To further confirm our findings obtained with the human
pDC cell line, we conducted experiments with primary human
pDCs from healthy blood donors as well. Primary pDCs were
cultured in the presence or absence of mTOR inhibitors for 2 h
and then stimulated with 3p-hpRNA and polyI:C for 6 h. In line
with our observations on GEN2.2 cells, inhibition of mTORC1
with rapamycin or mTORC1/2 with AZD8055 alone did not
influence the levels of IFN-α, IL-6 and TNF. Furthermore, mTOR
blockade decreased the 3p-hpRNA stimulated (Figure 8A) and
polyI:C triggered (Figure 8B) release of IFN-α as well as
the secretion of IL-6 and TNF pro-inflammatory cytokines.
These data demonstrate that both selective mTORC1 and
dual mTORC1/2 inhibition affects similarly the RLR-triggered
cytokine responses of pDCs.
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FIGURE 5 | RLR stimulation increases mTORC1 and mTORC2 activity in GEN2.2 cells that can be effectively inhibited by rapamycin and AZD8055 pre-conditioning.
GEN2.2 cells were pre-treated with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h and then stimulated with 3p-hpRNA (0.5 µg/ml)
(A,B) or polyI:C (1 µg/ml) (C,D) in a time-dependent manner. Kinetics of p70S6K and Akt phosphorylation was determined by western blotting. (A,C) Representative
blots are shown. (B,D) Bar graphs represent the mean ± SD from 4 independent experiments. Specific bands for Akt are indicated by arrows. *p < 0.05,
**p < 0.01, ***p < 0.01, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001. ND, not determined.
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FIGURE 6 | The RLR-mediated production of IFN-α and pro-inflammatory cytokines is decreased upon mTOR inhibition in GEN2.2 cells. GEN2.2 cells were
pre-treated with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h then stimulated with 3p-hpRNA (0.5 µg/ml) (A), polyI:C (1 µg/ml) (B),
or VSV (MOI 1) (C). (A–C) IFN-α, IL-6 and TNF protein levels were measured by ELISA 6 h after 3p-hpRNA as well as polyI:C activation and 18 h after VSV
stimulation. Data are shown as mean ± SD from 4 to 8 independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01,
###p < 0.001, ####p < 0.0001. ND, not determined.
Rapamycin Is a Stronger Inhibitor of
DC-Mediated T Cell Responses Then the
Dual mTORC1/mTORC2 Kinase Inhibitor
AZD8055
Having established that mTOR blockade impaired the production
of type I IFNs and pro-inflammatory cytokines induced by
RLR stimulation, next, we sought to investigate the capacity of
moDCs and primary pDCs to promote T cell responses upon
mTOR inhibition. Therefore, allogeneic naïve CD8 + T cells
were co-cultured with DCs treated as described above then the
proliferation and cytokine production of T cells were measured
by flow cytometry. In these experiments, DCs were stimulated
with synthetic ligands instead of live virus, since we cannot
exclude the possibility that T cells get infected with VSV in the
co-culture. Our results demonstrate that moDCs treated with
3p-hpRNA (Figures 9A,B) or polyI:C (Figures 9C,D) induced
significant T cell proliferation, which was inhibited when moDCs
were pre-treated with rapamycin prior to RLR stimulation.
On the contrary, the active site inhibitor AZD8055 was much
weaker in inhibiting the ability of moDCs to stimulate T cell
proliferation. Similarly, rapamycin effectively reduced, whereas
AZD8055 did not affect RLR-stimulated pDCs (Figures 9E–H)
in their capacity to induce T cell proliferation.
In parallel experiments, we also analyzed the effector
functions of DC-stimulated CD8 + T cells by measuring
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FIGURE 7 | RLR stimulation increases the phosphorylation of TBK1 that is reduced by rapamycin and AZD8055 pre-treatment in GEN2.2 cells. Cells were
pre-treated with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h then stimulated with 3p-hpRNA (0.5 µg/ml) (A,C) or polyI:C (1 µg/ml)
(B,D) for different time periods. Kinetics of TBK1 phosphorylation were determined by western blotting. (A,B) Representative blots are shown. (C,D) Bar graphs
represent the mean ± SD of at least 3 independent experiments. **p < 0.01, ****p < 0.0001 vs. control; #p < 0.05, ###p < 0.001, ####p < 0.0001. ND, not
determined.
intracellular levels of the pro-inflammatory cytokine IFN-y and
the cytotoxic protein Granzyme B. MoDCs activated with 3p-
hpRNA (Figures 10A–D) or polyI:C (Figures 10E–H) triggered
the production of high levels of IFN-y and Granzyme B in
T cells. Intriguingly, the T cell activating capacity of moDCs
was significantly impaired upon rapamycin pre-treatment,
whereas was not affected by AZD8055 pre-conditioning. We
obtained very similar results with pDCs, the ability of which
to promote IFN-y and Granzyme B production in T cells was
diminished upon rapamycin but not by AZD8055 pre-treatment
(Figures 11A–H). All these observations reveal that mTORC1 but
not mTORC1/C2 inhibition is required to inhibit effectively the T
cell stimulatory potential of human DCs.
DISCUSSION
DCs are potent antigen presenting cells and thus play a critical
role in orchestrating innate and adaptive immune responses
against viruses (35). For the reason that many viruses replicate in
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FIGURE 8 | The RLR-stimulated secretion of IFN-α and pro-inflammatory cytokines is abolished upon mTOR blockade in primary human pDCs. Primary pDCs were
pre-treated with vehicle control, 100 nM rapamycin (RAPA) or 100 nM AZD8055 (AZD) for 2 h and then stimulated with 3p-hpRNA (0.5 µg/ml) (A) or polyI:C
(1 µg/ml) (B). (A,B) IFN-α, IL-6 and TNF protein levels were measured by ELISA 6 h after stimulation. Data are shown as mean ± SD from 3 independent
experiments. **p < 0.01, ***p < 0.01, ****p < 0.0001 vs. control; #p < 0.05, ##p < 0.01, ####p < 0.0001. ND, not determined.
the cytoplasm, host cells have had to evolve mechanisms to detect
pathogens intracellularly as well. Upon reaching the cytoplasm,
viral nucleic acids can be sensed by RLRs, which are key elements
of host defense by triggering innate immune responses to control
and eliminate viral infections (36). Following activation RIG-I or
MDA5 initiate a cascade of downstream signaling events leading
to the production of type I IFNs and pro-inflammatory cytokines
that altogether elicit an antiviral state to eradicate the virus from
the host (37). In the last decade, mTOR has been emerged as a
central regulator of TLR-mediated DC maturation and function,
how it affects RLR-dependent antiviral signaling of human DCs
has not been explored yet.
Previous results showed that the PI3K/mTOR pathways
regulates various aspects of DC biology including differentiation,
maturation, cytokine production and T cell stimulatory potential
of DCs as well (38). The very first study describing a link
between TLR signaling and mTOR activity in DCs showed that
stimulation of pDCs with the TLR9 ligand CpG-A enhanced
the phosphorylation of p70S6K, the major downstream target of
mTORC1, which was inhibited upon rapamycin pre-treatment
(9). Subsequent studies also demonstrated that various TLR
ligands are able to induce p70S6K phosphorylation, which was
abrogated by rapamycin in both human and murine DCs.
TLR ligands also activate mTORC2 in different innate immune
cells such as monocytes, macrophages and DCs (39–42). For
instance, studies have demonstrated that stimulation of mouse
BM-DCs with the TLR4 agonist lipopolysaccharide induced the
phosphorylation of Akt on serine 473, which is a commonly used
readout for mTORC2 activity (42, 43). Moreover, several viruses
are also able to activate the PI3K/Akt/mTOR signaling to promote
cell survival and inhibit apoptosis (44, 45). It has been published
that infection of lung epithelial cells with Sendai virus, which is
primarily recognized by RIG-I but can also be detected by MDA5
and TLR7, induces the phosphorylation of several mTOR kinase
substrates suggesting increased mTOR activity (46). Previous
studies also confirmed that mTORC1 is a key factor in regulating
the replication of coronaviruses, the replication intermediates of
which are suggested to be recognized by RLRs (47, 48). Here we
demonstrate that similar to TLR triggering, RLR stimulation of
human DCs also results in the activation of the mTOR signaling
pathway. We found that activation of moDCs and pDCs with
RIG-I/MDA5 specific ligands significantly increased p70S6k and
Akt phosphorylation, which reflects enhanced mTORC1 and
mTORC2 activity, respectively.
The mTOR signaling network has been found to play a
central role in coordinating DC metabolic reprogramming in
response to microbial stimuli (49, 50). We have previously
reported that RIG-I stimulation of moDCs but not of pDCs is
also accompanied by an increase in glycolysis (23), thus we have
tested how mTOR inhibition affects the RLR-driven metabolic
shift toward glycolysis in moDCs. Both rapamycin and AZD8055
reduced significantly the RLR-mediated release of lactate and
upregulation of glycolysis related genes that reflects decreased
glycolytic rate upon mTOR blockade.
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FIGURE 9 | Rapamycin but not AZD8055 effectively inhibits the ability of RLR-stimulated moDCs and primary pDCs to induce proliferation of naive T cells.
CFSE-labeled naïve CD8 + T cells were co-cultured with allogeneic moDCs (A–D) and primary pDCs (E–H) pre-treated with the indicated reagents. After 5 days of
co-cultivation, cell division was measured by flow cytometry. (A,C,E,G) Representative histograms are shown where numbers indicate the percentage of viable
dividing T cells. In A and C T cell controls are the same, since representative dot plots originate from the same set of experiment from one single donor. (B,D,F,H)
Bar graphs represent the mean ± SD of at least 6 independent experiments. *p < 0.05, **p < 0.01, ****p < 0.0001 vs. control; ###p < 0.001, ####p < 0.0001. AZD:
AZD8055, RAPA: rapamycin.
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FIGURE 10 | Rapamycin but not AZD8055 decreased the T cell activating capacity of RLR-activated moDCs. Naïve CD8 + T cells were co-cultured with allogeneic
moDCs pre-treated with the indicated reagents. After 6 days of co-cultivation T cells were stimulated with phorbol myristate acetate (0.1 µg/ml) and ionomycin
(1 µg/ml) in the presence of monensin for 5 h. IFN-y and Granzyme B production of CD8 + T cells was measured by intracellular cytokine staining using flow
cytometry. (A,C,E,G) Data from one representative experiment are shown. Numbers in quadrants indicate percent cells in each. In A and E as well as in C and G T
cell controls are the same, since representative dot plots originate from the same set of experiment from one single donor. (B,D,F,H) Bar graphs represent the
mean ± SD of 6 independent experiments. ***p < 0.01, ****p < 0.0001 vs. control; ####p < 0.0001. AZD: AZD8055, RAPA: rapamycin.
There are several and sometimes controversial reports about
the ability of mTOR to control the phenotypic profile and
cytokine producing properties of different DC subtypes. In
pDCs and Fms-like tyrosine kinase 3 ligand-dependent DCs
inhibition of mTOR or its downstream target p70S6K have
been shown to impair TLR9-mediated type I IFN production
(9, 10). In moDCs, short term blockade of mTOR leads to
a decrease in their inflammatory cytokine production such as
IL-6 and TNF after stimulation of various cell surface TLRs.
On the contrary, rapamycin pre-treatment of CD1c + cDCs
Frontiers in Immunology | www.frontiersin.org 15 September 2020 | Volume 11 | Article 572960
fimmu-11-572960 September 9, 2020 Time: 19:41 # 16
Fekete et al. mTOR Regulates RLR-Mediated Responses
FIGURE 11 | The T cell activating capacity of RLR-stimulated primary human pDCs is decreased by rapamycin but not AZD8055 pre-treatment. Naïve CD8 + T cells
were co-cultured with allogeneic primary human pDCs pre-treated with the indicated reagents. After 6 days of co-cultivation T cells were stimulated with phorbol
myristate acetate (0.1 µg/ml) and ionomycin (1 µg/ml) in the presence of monensin for 5 h. IFN-y and Granzyme B production of CD8 + T cells was measured by
intracellular cytokine staining and flow cytometry. (A,C,E,G) Data from one representative experiment are shown. Numbers in each quadrant represent the
percentage of cells. In A and E as well as in C and G T cell controls are the same, since representative dot plots originate from the same set of experiment from one
single donor. (B,D,F,H) Bar graphs represent the mean ± SD of 6 independent experiments. ***p < 0.01, ****p < 0.0001 vs. control; ####p < 0.0001. AZD:
AZD8055, RAPA: rapamycin.
increased TLR4-induced production of IL-6, while did not affect
TNF secretion (11). In addition, we have previously reported
that mTOR is essential to the production of type I and III
IFNs in both moDCs and CD1c + cDCs following endosomal
TLR3 stimulation (14). A possible link between mTOR and
RLR signaling was suggested in a previous study, in which
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rapamycin pre-treatment was reported to decrease the polyI:C-
induced secretion of IFN-α in mouse macrophages lacking the
TLR3 adaptor molecule TRIF (10). The results obtained from
our current study clearly demonstrate that mTOR also acts as a
crucial regulator of RLR-mediated cytokine responses in human
DCs since both rapamycin and AZD8055 decreased significantly
the RLR-mediated secretion of IFN-α, IL-6 and TNF of moDCs
and pDCs. Consistent with that, upon infection of DCs with live
replicating VSV, which is known to be specifically recognized by
RIG-I rather than by MDA5 (15), we also observed impaired
cytokine production in the presence of mTOR inhibitors. In
line with our data, other studies previously reported that mTOR
inhibition reduced the VSV-triggered production of IFN-α in
Flt3-ligand-dependent DCs (10) and decreased the type I and
III IFN production of human lung epithelial cells in response
to Sendai virus infection (46). To reveal how mTOR regulates
the RLR-mediated cytokine responses of DCs we have measured
the activity of TBK1, which leads to the activation of nuclear
factor-kappa B (NF-kB) and interferon regulatory factor 3
(IRF3) transcription factors and eventually to the production
of pro-inflammatory cytokines and type I IFNs (28, 29). Our
results show that mTOR blockade reduces the RLR-triggered
phosphorylation of TBK1, thus we suppose, that mTOR regulates
the cytokine production of DCs via inhibiting the RLR-initiated
phosphorylation of TBK1. These data demonstrate that mTOR
signaling is critical for the antiviral cytokine response of various
cell types including DCs.
In contrast to cytokine responses, we could not detect
significant alterations in the phenotype of RLR-stimulated
DCs upon mTOR inhibition. Nevertheless, previous studies
including ours have reported changes in the cell surface molecule
expression of TLR-triggered DCs. Previously we have found
that the levels of CD83, a frequently used DC maturation
marker, was increased in CD1c + cDCs but was unaltered in
moDCs upon rapamycin pre-conditioning (14). In line with
these data, our present study demonstrates that RLR-mediated
upregulation of CD83 is unaffected in moDCs by rapamycin
or AZD8055 pre-conditioning. Interestingly, in RLR-stimulated
pDCs rapamycin did not affect while AZD8055 increased the
expression of CD83. All the other tested cell surface molecules,
including costimulatory, MHC class I and II proteins were not
affected by mTOR inhibition either in moDCs or pDCs indicating
that mTOR blockade does not interfere with the RLR-triggered
phenotypic changes of human DCs. All these data suggest that
mTOR-mediated effects on the phenotype of DCs vary greatly
depending on the cell type, mode of activation and type of
receptor stimulated.
Data from many studies indicate that mTOR is also involved
in the antigen presentation by DCs and thereby able to modulate
their ability to stimulate effector T cell responses (38). The
cytokine milieu created by DCs in response to viral infection
acts in collaboration with the antigenic signal to drive the
differentiation and survival of antiviral CD8 + T cells (51).
Importantly, type I IFNs play a major role in T cell responses
against viral infected cells by allowing the clonal expansion
and prolonging the survival of effector CD8 + T cells (52).
Since mTOR inhibition decreased the RLR-driven production
of IFN-α by DCs, we were curious how their CD8 + T cell
stimulatory capacity is affected. Our co-culture experiments
demonstrate that rapamycin effectively reduces the ability of
RLR-stimulated moDCs and pDCs to prime CD8 + T cell
proliferation. Interestingly, the dual mTOR kinase inhibitor
AZD8055 only slightly decreased the T cell proliferation capacity
of RLR-stimulated moDCs, while not affecting pDCs. In line
with our observation another study demonstrated that rapamycin
is a more potent inhibitor of BM-DC-mediated CD8 + T cell
proliferation then the dual mTOR kinase inhibitor AZD2014,
which must be applied in a dose 20-fold higher than rapamycin
to achieve a similar inhibitory effect (12). Nevertheless, it must be
noted that higher doses of mTOR inhibitors show greater toxicity
(53). In line with these observations we found that AZD8055
at doses greater than 100 nM decreased moDCs survival
significantly (data not shown). Similarly, Torin-1, another ATP-
competitive mTOR inhibitor was less effective than rapamycin to
reduce the T cell stimulatory capacity of TLR4-stimulated BM-
DCs (54). Moreover, AZD8055, but not rapamycin combined
with an agonist CD40 antibody elicited synergistic antitumor
response in a metastatic renal cell carcinoma model (55).
Analyzing the DC-mediated effector functions of T cells, we also
found that rapamycin significantly decreased, whereas AZD8055
did not affect the ability of RLR-stimulated DCs to induce
IFN-γ and Granzyme B production by CD8 + T cells. This
phenomenon could be possible explained by the loss of an
mTORC2-mediated negative feedback loop that is suppressed by
dual mTOR kinase inhibitors. Recently, the NPV-BEZ235 dual
PI3K/mTOR kinase inhibitor was demonstrated to overactivate
the mitogen-activated protein kinase kinase (MEK)/extracellular
signal-regulated kinase (ERK) pathway in human pancreatic
cancer cells (56). Stimulation of DCs via PRRs leads to the
activation of various MAPKs and among them the MEK/ERK
signaling pathway was demonstrated to act as a positive regulator
of antigen presentation in moDCs. Interestingly, blockade of
mTORC2 alone seems to enhance rather than inhibit the ability
of DCs to promote T cell responses. For instance, absence
of mTORC2 in cutaneous DCs elicited enhanced CD8 + T
cell effector responses and augmented skin graft rejection (57).
In addition, mTORC2 deficient mouse myeloid DCs exhibited
enhanced T cell allostimulatory ability and increased capacity
to expand IFN-γ- and IL-17-producing T cells following TLR
and non-TLR stimulation (58). Though, the mechanism behind
the increased immunogenicity of mTORC2-deficient DCs has
not been revealed yet. Thus, further studies are needed to reveal
the mechanism underlying the diverse effects of single mTORC1
and dual mTORC1/C2 inhibitors on the antigen presenting
capacity of DCs.
Our findings describe for the first time, that mTOR
kinase activity is increased upon RLR stimulation of human
DCs. Furthermore, we show that mTOR plays an essential
role in the regulation of RLR-mediated antiviral and pro-
inflammatory cytokine production of human DCs. Here we
also demonstrate that rapamycin greatly reduces the capacity of
RLR-stimulated DCs to promote T cell responses, however the
dual mTORC1/mTORC2 inhibitor failed to do so. Intriguingly,
rapamycin and its derivative everolimus, which are commonly
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used for maintaining immunosuppression following solid
organ transplantation has been proven to be effective in the
management of viral infections that result from reactivation
of latent viruses in transplant recipients (59). Very recently
rapamycin (also known as sirolimus) has been also suggested as
a potential candidate for treating COVID-19 infected patients
based on a network-based drug repurposing model (60).
However, further studies and clinical trials are needed to
evaluate the effectiveness of mTOR inhibitors for protection
against viral infections. Rapamycin is also used to induce the
ex vivo generation of tolerogenic DCs, which are promising
candidates for treatment of allergic diseases, for prevention
of transplant rejection and are in clinical trials for therapy
of autoimmune disorders (61). Meanwhile, dual mTOR kinase
inhibitors are being tested in clinical trials to treat various types
of human cancer, to prevent organ rejection and to control
autoimmune diseases (62). These previous findings and our novel
observations suggest that the distinct impacts of first and second
generation mTOR inhibitors on immune cell functionality should
be considered in the development of new generation mTOR
inhibitors for any clinical applications.
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